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Tanshinone IIA (Tan IIA) is a member of the major lipophilic components extracted from the root of Salvia miltiorrhiza Bunge,
which is currently used in China and other neighboring countries to treat patients suﬀering from myocardial infarction (MI),
angina pectoris, stroke, diabetes, sepsis, and other conditions. However, Tan IIA is not easy to be absorbed through intestinal
pathway. To raise the bioavailability of the herb, sodium tanshinone IIA sulfonate (STS) was developed. This paper discussed the
pharmacology of Tan IIA, STS, and their potential cardioprotective eﬀects.
1.Introduction
Salvia miltiorrhiza Bunge (Danshen) belongs to the Labiatae
family of the plant kingdom. It is considered to have the
function of activating blood circulation and removing blood
stasis, entering the “heart”, “pericardium”, and “liver” chan-
nels according to the theory of traditional Chinese medicine
(TCM). Danshen has been widely used in oriental countries,
especially China, to treat various circulatory disturbance-
related diseases for its special pharmacological actions,
including vasodilatation, anticoagulation, antiinﬂammation,
and free radical scavenging. In recent years, traditional
medicines have been playing more and more important roles
in the maintenance of health, the prevention and treat-
ment of diseases, as well as plant-based drug discovery [1, 2].
Although many practitioners are used to prescribing nature
products, more and more doctors and researchers are
fascinated in chemical compounds of Salvia miltiorrhiza
Bunge.
There are two main active compounds: the lipophilic
(Tanshinone I, IIA, IIB; cryptoTanshinone; other related
compounds) and the hydrophilic (polyphenolic acids, dan-
shensu, protocatechuic aldehyde, and protocatechuic acid).
Tanshinone IIA (Tan IIA), which is a member of the major
lipophilic components extracted from Salvia miltiorrhiza
Bunge, has indicated signiﬁcant therapeutic eﬀects on vari-
ous diseases in vivo and in vitro. Since Tan IIA is not easy to
be absorbed through intestinal pathway, sodium tanshinone
IIAsulfonate(STS)wasdevelopedtoraisethebioavailability.
T h ec h e m i c a ls t r u c t u r eo fS T Si ss h o w ni nF i g u r e1. In this
paper,thepharmacologyofTanIIAandSTSinthetreatment
for cardiovascular diseases was reviewed.
2.CardiovascularPharmacology
2.1. Vasodilative Eﬀect. Cheng et al. [3] demonstrated that
Tan IIA produced a concentration-dependent relaxation in
isolated spontaneously hypertensive rat (SHR) aortic rings
precontracted with phenylephrine or potassium chloride
(KCl) through ATP-sensitive K(+) channel to lower
[Ca(2+)]i. Wu et al. [4] investigated the eﬀects of Tan IIA
on isolated rat coronary arteriole and the underlying mech-
anisms. The results showed that endothelium denudation,
inhibition of nitric oxide synthase (NOS), inhibition of the
cytochrome P450 epoxygenase, and blockade of the large
conductance Ca(2+)-activated potassium channels (BKca)
signiﬁcantly decreased the vasodilation elicited by Tan IIA,
which indicated that Tan IIA induces an endothelium-
dependent vasodilation in coronary arterioles; nitric oxide





Figure 1: The chemical structure of STS.
the vasodilation; activation of BKca channels plays an
important role in the vasodilation. Kim et al. [5]c o n c l u d e d
that topical Tan IIA increased both normalized arteriolar
diameter and periarteriolar NO concentration in the two–
kidney, one-clip renovascular hypertension model. N(G)–
monomethyl-L-arginineinhibitedTanIIA-inducedvasodila-
tion. Tan IIA prevented the hypertension-induced reduction
of endothelial NOS (eNOS) and increased eNOS expression
to levels higher than sham-operated control. Topical Tan IIA
increased normalized arteriolar diameter more in the cre-
master muscle of control mice than that in cremasters of
eNOS knockout mice. In ECV-304 cells transfected with
eNOS-green ﬂuorescent protein, Tan IIA signiﬁcantly in-
creased eNOS protein expression and eNOS phosphoryl-
ation. The results also indicated that eNOS stimulation was
one mechanism by which Tan IIA induced vasodilation and
reduces blood pressure.
2.2. Inhibition of Left Ventricular Hypertrophy. Accumulative
studies had demonstrated that Tan IIA could inhibit left
ventricular hypertrophy (LVH) with diﬀerent mechanisms.
Overwhelming postloading is a main factor promoting LVH,
therefore controlling hypertension is very important in LVH
inhibition. Tan IIA has shown vasodilatation eﬀect through
adenosine triphosphate (ATP)-sensitive K(+) channel to
lower the concentration of Ca2+ in myocytes, regulate the
condition of hypertension, and inhibit the formation of
hypertrophy [3]. Tan IIA could also prevent LVH through
inhibitingangiotensinreceptor(ATR)expressionorblocking
free Ca2+ inﬂux in rats with hypertrophic myocardium caus-
edbyabdominalaortaconstriction,anditseﬀectonlowering
hypertension had no signiﬁcant diﬀerence compared with
Valsartan [6, 7]. Additionally, Tan IIA has been reported to
block the transforming growth factor (TGF) beta1/Smads
signal pathway and inhibit the formation of myocardial
hypertrophy [7], attenuate enhanced collagen type I expres-
sion and collagen synthesis as well as depressed matrix
metalloproteinase-1 (MMP-1) expression and activity by
angiotensin II (Ang II) [8]. Furthermore, Tan IIA depressed
the intracellular generation of reactive oxygen species (ROS),
nicotinamide adenine dinucleotide phosphate (NADPH)
oxidase activity, and subunit p47 (phox) expression, which
are the factors inducing LVH. Fang et al. [9]c o n c l u d e d
that Tan IIA conferred its beneﬁcial eﬀects on the collagen
metabolism probably through its regulation of transcript
levels of the MMPs/tissue inhibitor of metalloproteinases
(TIMPs) balance. Although the balance regulation had no
diﬀerence as compared with Valsartan, Tan IIA showed
slight improvement in attenuating cardiac dysfunction. At
least three studies assessed proto-oncogene c-fos mRNA ex-
pression of cardiocytes when investigated the mechanism
of Tan IIA, indicating that Tan IIA could prevent LVH in-
duced by Ang II, which might be related to its inhibition of
proto-oncogene expression [10–12]. Similar conclusion was
drawn by Tu et al. [13] that Tan IIA had the deﬁnite func-
tion in preventing LVH by its action on the protein kinase B
(PKB/Akt) signaling pathway, which could regulate the ex-
pression of proto-oncogene c-fos. Two in vitro studies
[14, 15] had demonstrated that Tan IIA dose-dependently
inhibited the increment of the total protein level induced
by Ang II and the p-extracellular signal regulatory kinase
(ERK)1/2 expression stimulated by Ang II, which indicated
the mechanism that Tan IIA inhibited the myocardial cell
hypertrophy induced by Ang II may be associated with the
inhibition of p-ERK1/2.
2.3. Restraining Smooth Muscle Cell Proliferation and Intimal
Hyperplasia. Tan IIA could signiﬁcantly decrease intimal
thickening, suppress cell proliferation and migration, inhibit
the expression of various growth factors, induce the diﬀer-
entiation, maturity, and apoptosis of the vascular smooth
muscle cell (VSMC), and ameliorate the function and condi-
tion of vascular smooth muscle [16]. Since there are so many
beneﬁcial eﬀects on VSMC, Tan II is playing an important
role in the treatment of arteriosclerosis, restenosis after
angioplasty or stenting, brain arteriovenous malformations,
and pulmonary hypertension. However, the mechanism of
Tan II has not been very clear. Various studies [17–21]
had found that Tan IIA could suppress cell proliferation
and BrdU incorporation into DNA, block cell cycle in
G0/G1 phase, and inhibit ERK1/2 phosphorylation and c-
fos expression. Initial proliferation might be inhibited by
blocking mitogen-activated protein kinase (MAPK) signal-
ing pathway and downregulating c-fos expression. Pan et al.
[22] demonstrated that Tan IIA could signiﬁcantly inhibit
the proliferation of VSMCs in a dose-dependent manner,
and the mechanism might be related to the downregu-
lation of calponin (CaN) activities and the inhibition on
calcineurin mRNA and proliferating cell nuclear antigen
(PCNA) expressions. Jin et al. [23] illuminated that Tan
IIA exhibited multiple eﬀects on inhibiting human aortic
SMCs migration, the mechanisms of which might inhibit
IkappaBalpha phosphorylation and p65 nuclear transloca-
tion through inhibition of Akt phosphorylation, suppress
tumor necrosis factor-alpha (TNF-α)-induced ERK and
c-jun phosphorylation, and block nuclear factor-kappaB
(NF-κB) and activator protein-1 (AP-1) DNA-binding; all
these factors played important roles in human aortic SMCs
migration.
2.4. Attenuation of Atherosclerosis. In addition to VSMC pro-
liferation and intimal hyperplasia, injury of vascular endo-
thelium, lipid deposition, oxidative stress, and inﬂammatory
reaction also play important roles in the formation andEvidence-Based Complementary and Alternative Medicine 3
progression of atherosclerosis. Endothelial cells can secrete
two kinds of substances with opposite functions, one can in-
duce VSMC apoptosis (such as NO), and the other can
inhibit VSMC apoptosis (such as endothelin-1 (ET-1), Ang
II, and growth factors). Unbalance between them decides
whether endothelium is injured. NO is the key factor in
signal transduction, it can relax blood vessels and activate
genes relative to VSMC apoptosis. Li et al. [24]a n dH u a n g
et al. [25] concluded that Tan IIA could inhibit the negative
eﬀect of Ang II on NO production and eNOS expression
in porcine aortic endothelial cells. Another in vitro study
showed that Tan II might inhibit ET-1 production and cell
apoptosis, inducing protective eﬀect on vessel endothelium
[26]. Tan IIA could also reduce plaque area in endothelium,
decreaselipiddeposition,andsigniﬁcantlyinhibittheforma-
tion of atherosclerosis, although the level of total cholesterol
(TC), triglyceride (TG), low-density lipoprotein cholesterol
(LDL-C), and high-density lipoprotein cholesterol (HDL-C)
in serum had not been changed by Tan IIA [27].
To verify the antioxidant eﬀect on atherosclerosis forma-
tion, at least ﬁve experiments [28–32] had been established.
Tang et al. [28] demonstrated that Tan IIA could attenuate
atheroscleroticlesioninapolipoproteinE(apoE)(−/−)mice,
which might be attributed to its properties of both antiox-
idation and downregulation of scavenger receptors. Fur-
thermore, antagonism of peroxisome proliferators-activated
receptor gamma (PPARγ) might be involved in the down-
regulation of CD36 by Tan IIA. Fang et al. [29] found that
thesuperoxidedismutase(SOD)activitywassigniﬁcantlyin-
creased while the level of malondialdehyde (MDA) was de-
creased in Tan IIA group, which showed that antioxidant
eﬀect of Tan IIA might be a potential mechanism involved
in antiatherosclerosis. Tang et al. [30] suggested that Tan II
A signiﬁcantly attenuated the atherosclerosis in rat model,
which might be attributed to its inhibition of oxidized low
density lipoprotein (oxLDL) production, independent of
the serum levels of lipids, calcium, and 25-OH Vitamin D.
Increasing of Cu/Zn SOD activity as well as mRNA and
protein expression by Tan IIA might protect LDL against
oxidation induced by superoxide anion in vessel. Active
oxygen free radical is a major factor inducing endothelial
injury; hydrogen peroxide can promote the formation of
free radicals, which can penetrate cell membrane, combine
with Fe2+ or Cu2+, induce lipid peroxidation, and lead to
endothelium injury and formation of atherosclerosis ﬁnally.
Lin et al. [31, 32] indicated that Tan IIA could protect ECV-
304 cell damage induced by hydrogen peroxide through its
anti-oxidant eﬀect and CD40 anti-inﬂammatory approach.
Inﬂammatory eﬀect can induce endothelium injury,
foam-cell appearance, and leukocytes adhesion, all of which
play important roles in the formation of atherosclerosis. At
least two studies [29, 33] had veriﬁed that Tan IIA could
decrease inﬂammatory eﬀect and attenuate atherosclerosis of
vessels. Fang et al. [29] indicated that expression reduction
of CD40 and MMP-2 activity might be the potential mech-
anismsofantiatherosclerosiseﬀectofTanIIA.Fangetal.[33]
demonstrated that Tan IIA could dose-dependently inhibit
atherosclerotic lesion through downregulation of protein
expression and activities of MMP-2 and MMP-9 as well as
serum VCAM-1 and interleukin (IL)-1β in rabbits fed high-
fat diet.
Platelet activation and aggregation can accelerate the
formation of atherosclerosis. Jiang et al. [34] indicated that
Tan IIA could inhibit the increasing P-selectin expression of
thrombin-activated platelets in a concentration-dependent
manner,whichmayalsobeamechanismofTanIIAtoinhibit
atherosclerosis.
2.5.Lipid-LoweringEﬀect. Kang et al. [35]demonstratedthat
human HepG2 cells treated with Tan IIA for 24h exerted a
dose-dependentinhibitoryeﬀectonapolipoproteinB(apoB)
secretion together with TG. However, another secretory
protein, albumin, was unaﬀected by Tan-IIA treatment,indi-
cating that the eﬀect of Tan IIA is speciﬁc for apoB secretion.
Tan IIA decreased the transcription level of microsomal TG
transfer protein gene, suggesting that lipoprotein assembly
is likely to be involved in the inhibited ApoB secretion.
Gong et al. [36] reported that Tan IIA inhibited 3T3-L1
preadipocyte diﬀerentiation and transcriptional activities of
full-length PPARγ and PPARγ ligand-binding domains. The
eﬀects of Tan IIA are mediated through its property as a
natural antagonist of PPARγ. Tan IIA treatment reduced
adipose mass and body weight, improved glucose tolerance,
and lowered the LDL/HDL ratio without changing the food
intake in a high-fat-diet-induced obese animal model.
2.6. Inhibitory Eﬀect on the Inﬂammatory Responses. Vari-
ous studies demonstrated that inﬂammatory response was
involved in the process of myocardial infarction (MI), endo-
thelium injury, atherosclerosis, and cardiovascular hypertro-
phy [23, 29, 33, 37, 38], which have been mostly introduced
in the former paragraphs. However, mechanisms underlying
this eﬀect have not been fully understood. NF-κBa c t i v a t i o n
by NF-κB-inducing kinase (NIK)-lkappaB alpha kinase
(IKK) pathway and MAPKs pathway is known to be involved
in the inﬂammatory response. Jang et al. [39] determined
the inhibitory eﬀect of Tan IIA on the activation of NF-
κB and IkappaB alpha phosphorylation and also examined
phosphorylation of NIK and IKK as well as the activation
of MAPKs such as p38 MAPK (p38), ERK1/2, and c-Jun N-
terminal kinase (JNK) in RAW 264.7 cells stimulated with
Lipopolysaccharides (LPS). The result suggested that Tan
IIA might inhibit LPS-induced lkappaB alpha degradation
and NF-κB activation via suppression of the NIK-IKK path-
way as well as the MAPKs (p38, ERK1/2 and JNK) pathway
in RAW264.7 cells, and these properties might provide a
potential mechanism which could explain the anti-inﬂam-
matory activity of Tan IIA. Another in vitro study [40]
suggested that Tan IIA had a similar structure with 17 beta-
estradiol (E2) and the result indicated Tan IIA exerted anti-
inﬂammatory eﬀects by inhibition of inducible NOS (iNOS)
gene expression and NO production, as well as inhibition of
inﬂammatory cytokine (IL-1β,I L - 6 ,a n dT N F - α) expression
via estrogenreceptor-dependent pathway. Therefore,it could
serve as a potential selective estrogen receptor modulator
(SERM) to treat inﬂammation-associated neurodegenerative
and cardiovascular diseases without increasing the risk of4 Evidence-Based Complementary and Alternative Medicine
breast cancer. Similar results were demonstrated by other
studies [41, 42].
2.7. Antioxidant Eﬀect. Oxidation reaction was involved in
variouspathologicalmechanisms,inducingdiﬀerentdiseases
including MI,angina pectoris,andrestenosis afterPCI, LVH,
and so on. Tan IIA can inhibit these reactions, which have
been mentioned in the above experiments [8, 28–32]. To test
the hypothesis that Tan IIA can alter the expression and/or
activity of speciﬁc antioxidant enzymes to prevent cells from
oxidant damage, at least three experiments [38, 43, 44]w e r e
conducted and demonstrated that the cell protective eﬀect of
Tan IIA was mediated primarily by induction of glutathione
peroxidase (GPx) gene expression and activity, as well as
other antioxidant enzyme activities in the heart. At least four
experiments [44–47] indicated that Tan IIA could scavenge
the free radicals produced in the superoxide approach,
which might be one of the important mechanisms in myo-
cardiocyte damage. Other studies [30, 48] suggested that
TanIIAsigniﬁcantlyattenuatesmyocardiocyteorvasculocyte
damage, which might be attributed to its inhibition of ox-
LDL production.
2.8. Antiplatelet, Anticoagulant, and Antithrombotic Eﬀect.
Tan IIA can decrease the blood viscosity obviously, inhibit
the activation of thrombin, and promote ﬁbrin degradation;
it can inhibit the function of platelets and the formation
of thrombus. Li et al. [49] showed that Tan IIA could sig-
niﬁcantly decrease the platelet number, with eﬃcacy similar
to aspirin. Jiang et al. [34] also found that Tan IIA could
reduce the number of blood platelets by inhibiting P-selec-
tin expression in a concentration-dependent manner. Li et
al. [50] demonstrated that Tan IIA could inhibit the throm-
bus formation and platelet aggression in in vivo study, and
it exerted more signiﬁcant eﬀect on antiplatelet than antico-
agulation.
To investigate the eﬀects of Tan IIA on procoagulant
activity (PCA) of human ECV304 cells induced by acute pro-
myelocytic leukemia cell line NB4 cells, Zhang et al. [51]
showed that the conditional media of NB4 cells treated with
Tan IIA (Tan IIA-NB4-CM) can increase the levels of PCA
and tissue factor (TF) activity of ECV304 cells through some
unidentiﬁed factor; however, Tan IIA can obviously decrease
the PCA and TF activity of ECV304 cells induced by Tan IIA-
NB4-CM.
CD41 and CD62p are two of the most important inﬂam-
matory factors, which can induce platelets aggregation and
promote blood coagulation. Jia et al. [52] found that Tan IIA
could decrease the expression of CD41 and CD62p, which
might inhibit platelet aggregation and blood coagulation.
2.9. Antiarrhythmia Eﬀect. Jia et al. [52] indicated that Tan
IIA could decrease the expression of adhesion molecule in
blood platelet to prevent arrhythmia. In addition, high-con-
ductance Ca2+-activated K+ channels (BKCa) in vascular
smooth muscle also play important roles in controlling
the vascular tone by determining the level of membrane
potential and Ca2+ inﬂux through voltage-gated Ca2+ chan-
nels. Agents that can alter the activity of Ca2+ channels or
BKCa thus aﬀect the vascular tone in both physiological and
pathological conditions. Experiments [53, 54] showed that
Tan IIA could block L-type Ca2+ channel, decrease concen-
tration of intracellular Ca2+, ameliorate calcium overload in
myocardiocytes,andpreventoreventreatarrhythmiaﬁnally.
Except for Ca2+ and K+, microRNA-1 (miR-1) level is also
one of the important factors in ischemic arrhythmia. Shan et
al. [55] indicated downregulation of miR-1 and consequent
recovery of Kir2.1 might account partially for the eﬃcacy
of Tan IIA in suppressing ischemic arrhythmia and cardiac
mortality. These ﬁndings support the proposal that miR-1
could be a potential therapeutic target for the prevention of
ischemicarrhythmias.Ongenelevel,Sunetal.[56]indicated
that Tan IIA could activate human cardiac KCNQ1/KCNE1
potassium channels (IKs) in HEK 293 cell directly and
speciﬁcally through aﬀecting the channels’ kinetics, which
would be a promising therapeutic medicine in arrhythmia.
2.10. Antimyocardial Hypoxia. Reducing oxygen consump-
tion and increasing the tolerance in hypoxygen of myocar-
diocytes are beneﬁcial to coronary heart disease. Huang
et al. [57] detected the left ventricle end diastole pressure
(LVEDP) after ligating coronary artery of dogs, the result
indicated Tan IIA could decrease LVEDP and heart volume
and reduce myocardial oxygen consumption. Shao et al. [58]
demonstrated that the activation of ATP enzyme in myo-
cardium was decreased in patient with hyperthyroidism;
however, Tan IIA could protect it and increase the tolerance
in hypoxygen of the myocardiocytes. Various studies [4, 59,
60] have suggested that Tan IIA might dilate coronary artery,
inhibit vascular contraction, increase coronary blood ﬂow
and reduce oxygen consumption of myocardiocytes with
diﬀerent mechanisms. Sun et al. [61] suggested that Tan
IIA could decrease intracellular calcium overload and K+
outﬂow, inhibit Na+ inﬂow, keep the balance of membrane
potential, and therefore protect myocardiocyte in hypoxia.
2.11. Reduction of Myocardial Infarct Size. Tan IIA can dilate
coronary artery and increase coronary blood ﬂow, which is
beneﬁcial for reducing MI size. Various experiments [62–
65] have demonstrated that Tan IIA might recover cardiac
function and reduce MI size signiﬁcantly with diﬀerent
mechanisms. Zhang et al. [62] indicated that the possible
mechanism responsible for the eﬀect of Tan IIA was asso-
ciated with the phosphatidylinositol 3-kinase (PI3K/Akt)-
dependent pathway, which was accompanied with decreased
cardiacapoptosisandinﬂammation.Inaddition,TanIIAwas
found to reduce MI size by 53.14 ± 22.79% as compared to
that in the saline control, simultaneously, and signiﬁcantly
prolonged the survival of cultured human saphenous vein
endothelial cells rather than human ventricular myocytes in
vitro (these cells were separately exposed to xanthine oxidase
(XO)-generated oxyradicals), which may suggest that Tan
IIA could reduce MI size through prolonging survival of
endothelial cells [63]. Xu et al. [64] have assessed the eﬀectof
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that Tan IIA could reduce MI size and myocardial ischemia
injury through promoting angiogenesis and upregulating
vascular endothelial growth factor (VEGF) expression. Jiang
et al. [65] found that Tan IIA might establish extensive
collateral circulation and increase blood ﬂow in ischemic
area.
2.12. Inhibiting Ischemia Reperfusion Injury. Ischemia reper-
fusion (IR) exerts disturbance of microcirculation and leads
to many diseases, including myocardial stunning and reper-
fusion arrhythmia. Production of oxygen free radicals, cal-
cium overload in myocytes, endothelial cell injury, adhesion
of leukocyte, energy supply reduction, mitochondrial dam-
age, and myocardiocytes apoptosis are considered to be in-
volved in this process. Tan IIA can inhibit the activation of
proteases and ameliorate calcium overload in myocytes,
which have been introduced in the previous paragraph [53,
54, 61]. In addition, Tan IIA can increase the SOD content
in the injured myocytes, decrease the MDA concentration,
and inﬂuence electron transfer reaction in mitochondria,
thus scavenge the free acids, reduce the lipid peroxidation,
and protect myocytes and vascular endothelial cells in the
IR process [45–47]. ET, which can induce constriction of the
vessel, increases signiﬁcantly in IR, and Tan IIA can inhibit
the production and release of ET, promote secretion of NO,
and decrease IR injury of the heart [24–26]. Jiang et al. [34]
indicated that Tan IIA could inhibit HL-60 cell adhesion
to human umbilical vein endothelial cells through concen-
tration dependently inhibiting TNF-alpha and ameliorate
microcirculation disturbance. Fu et al. [46] suggested that
Tan IIA might markedly inhibit H2O2-induced oxidation in
vitro, signiﬁcantly inhibit IR-induced cardiomyocyte apop-
tosis by attenuating morphological changes and reducing the
percentage of terminal transferase dUTP nick end-labeling
(TUNEL)-positive myocytes and caspase-3 cleavage, as well
as ameliorate IR injury by upregulating Bcl-2/Bax ratio.
3. FinalComments
In the beginning of 21st century, we are facing serious chal-
lenges of cardiovascular diseases (CVDs). Although it is be-
coming less lethal, CVD prevalence is incessantly increasing
and it is still the most common cause of death. As a repre-
sentative of complementary and alternative medicines, TCM
has a history of thousands of years and has made great con-
tributions to the health and wellbeing of the people and to
themaintenanceandgrowthofthepopulation.Itprovidesus
with great treasure of herbal medicines or natural products,
which can be served as lead compound or new drug
candidates in the battle against CVDs.
Herbal medicines with the function of activating blood
circulation (ABC) have been investigated extensively and
made remarkable achievements in recent years [66, 67].
Salvia miltiorrhiza Bunge is the most common used ABC
herb in China for treating CVDs and other circulatory
disturbance-related diseases. Tan IIA, which is a member of
the major lipophilic components extracted from Salvia mil-
tiorrhiza Bunge, has indicated signiﬁcant therapeutic eﬀects
and multiple pharmacological actions including vasodila-
tive, antithrombotic, anti-inﬂammation, antioxidant, anti-
ischemia, antiarrhythmia, antihyperplasia, antiatherosclero-
sis, and lipid-lowering eﬀect. Clearly, Tan IIA appears to be
a promising natural cardioprotective agent. Further research
is warranted to translate these beneﬁcial eﬀects into clinical
practice and deﬁnitely address the mechanisms of its mul-
titarget actions.
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